In early 2025, the British Medical Journal (BMJ) reported 82 UK deaths from adverse reactions to semaglutide and tirzepatide, ...

GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the best affordable stocks under $5 to buy for the next 3 years. BofA slashed ...

With more than eight global patents, TempraMed continues to scale commercial access to its proprietary technology-a compact, maintenance-free solution that protects temperature-sensitive injectable ...

Doctors say the class of medications that includes Ozempic and Zepbound still offers health benefits for people with diabetes ...

Time for your weekly edition of the Defector Funbag. Got something on your mind? Email the Funbag. You can also read Drew ...

Target expands protein and supplement sections as GLP-1 drugs like Ozempic reshape shopping habits, driving demand for ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Industry experts ...

Starting Jan. 1, 2026, Pennsylvania will limit GLP‑1 weight‑loss drugs under Medicaid — threatening access for thousands of ...

The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer's disease progression in the highly awaited EVOKE phase III trials, Novo Nordisk announced Monday. The company shared ...

GLP-1 side effects like constipation and muscle mass loss can lead to uncomfortable pelvic floor symptoms like bladder leakage and painful sex.

Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...

The celebrated comedian has been open about her weight loss journey, including the medications she has taken and an ...